Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.910
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
+0.030 (1.57%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Esperion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 403.14 | 332.31 | 116.33 | 75.48 | 78.45 | Upgrade
|
| Revenue Growth (YoY) | 21.31% | 185.66% | 54.14% | -3.79% | -65.53% | Upgrade
|
| Cost of Revenue | 177.08 | 114.84 | 129.37 | 145.89 | 120.19 | Upgrade
|
| Gross Profit | 226.06 | 217.48 | -13.04 | -70.42 | -41.75 | Upgrade
|
| Selling, General & Admin | 165.79 | 163.07 | 142.52 | 109.08 | 171.74 | Upgrade
|
| Operating Expenses | 165.79 | 163.07 | 142.52 | 109.08 | 171.74 | Upgrade
|
| Operating Income | 60.27 | 54.4 | -155.56 | -179.5 | -213.48 | Upgrade
|
| Interest Expense | -84.6 | -59.25 | -58.98 | -56.81 | -46.35 | Upgrade
|
| Interest & Investment Income | 3.5 | 7.6 | 4.4 | 2.4 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | 0.42 | 0.48 | 0.53 | 1.24 | Upgrade
|
| EBT Excluding Unusual Items | -20.84 | 3.17 | -209.66 | -233.38 | -258.49 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.41 | -0.28 | -0.01 | Upgrade
|
| Legal Settlements | - | - | - | - | -18.25 | Upgrade
|
| Other Unusual Items | - | -54.92 | - | - | 2.65 | Upgrade
|
| Pretax Income | -20.84 | -51.75 | -209.25 | -233.66 | -269.11 | Upgrade
|
| Income Tax Expense | 1.84 | - | - | - | - | Upgrade
|
| Net Income | -22.68 | -51.75 | -209.25 | -233.66 | -269.11 | Upgrade
|
| Net Income to Common | -22.68 | -51.75 | -209.25 | -233.66 | -269.11 | Upgrade
|
| Shares Outstanding (Basic) | 208 | 187 | 103 | 66 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 208 | 187 | 103 | 66 | 29 | Upgrade
|
| Shares Change (YoY) | 11.05% | 81.54% | 55.26% | 129.76% | 5.20% | Upgrade
|
| EPS (Basic) | -0.11 | -0.28 | -2.03 | -3.52 | -9.31 | Upgrade
|
| EPS (Diluted) | -0.11 | -0.28 | -2.03 | -3.52 | -9.31 | Upgrade
|
| Free Cash Flow | -13.09 | -23.97 | -135.49 | -174.83 | -263.81 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.13 | -1.31 | -2.63 | -9.13 | Upgrade
|
| Gross Margin | 56.07% | 65.44% | -11.21% | -93.30% | -53.21% | Upgrade
|
| Operating Margin | 14.95% | 16.37% | -133.72% | -237.83% | -272.13% | Upgrade
|
| Profit Margin | -5.63% | -15.57% | -179.87% | -309.58% | -343.04% | Upgrade
|
| Free Cash Flow Margin | -3.25% | -7.21% | -116.46% | -231.64% | -336.29% | Upgrade
|
| EBITDA | 60.38 | 54.47 | -155.4 | -179 | -212.87 | Upgrade
|
| EBITDA Margin | 14.98% | 16.39% | -133.58% | -237.17% | -271.35% | Upgrade
|
| D&A For EBITDA | 0.11 | 0.06 | 0.16 | 0.5 | 0.61 | Upgrade
|
| EBIT | 60.27 | 54.4 | -155.56 | -179.5 | -213.48 | Upgrade
|
| EBIT Margin | 14.95% | 16.37% | -133.72% | -237.83% | -272.13% | Upgrade
|
| Revenue as Reported | 403.14 | 332.31 | 116.33 | 75.48 | 78.45 | Upgrade
|
| Advertising Expenses | 25 | 25.5 | 15.6 | 11.3 | 13.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.